These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10509560)

  • 21. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dynamic changes of cellular HIV-1 DNA quantification during highly active antiretroviral therapy in Chinese HIV infected individuals].
    Chen X; Zheng Y; Mamadou D; He Y; Zhou H; Chen Z; Luo Y; He B; He M; Yao Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 May; 38(5):537-44. PubMed ID: 23719535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Jonas L; Meibohm A; Holder D; Schleif WA; Condra JH; Emini EA; Isaacs R; Chodakewitz JA; Richman DD
    JAMA; 1998 Jul; 280(1):35-41. PubMed ID: 9660361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
    Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
    AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
    Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
    J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.
    van Rossum AM; Niesters HG; Geelen SP; Scherpbier HJ; Hartwig NG; Weemaes CM; Veerman AJ; Suur MH; de Graeff-Meeder ER; Slieker WA; Hop WC; Osterhaus AD; Burger DM; De Groot R
    J Pediatr; 2000 Jun; 136(6):780-8. PubMed ID: 10839877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.
    Gulick RM; Meibohm A; Havlir D; Eron JJ; Mosley A; Chodakewitz JA; Isaacs R; Gonzalez C; McMahon D; Richman DD; Robertson M; Mellors JW
    AIDS; 2003 Nov; 17(16):2345-9. PubMed ID: 14571186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TTV viral load as a marker for immune reconstitution after initiation of HAART in HIV-infected patients.
    Madsen CD; Eugen-Olsen J; Kirk O; Parner J; Kaae Christensen J; Brasholt MS; Ole Nielsen J; Krogsgaard K
    HIV Clin Trials; 2002; 3(4):287-95. PubMed ID: 12187502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
    N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
    Vigano A; Vella S; Saresella M; Vanzulli A; Bricalli D; Di Fabio S; Ferrante P; Andreotti M; Pirillo M; Dally LG; Clerici M; Principi N
    AIDS; 2000 Feb; 14(3):251-61. PubMed ID: 10716501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART.
    Patterson BK; McCallister S; Schutz M; Siegel JN; Shults K; Flener Z; Landay A
    AIDS; 2001 Sep; 15(13):1635-41. PubMed ID: 11546937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
    Ibáñez A; Puig T; Elias J; Clotet B; Ruiz L; Martínez MA
    AIDS; 1999 Jun; 13(9):1045-9. PubMed ID: 10397534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.
    Calcaterra S; Cappiello G; Di Caro A; Garbuglia AR; Benedetto A
    J Infect; 2001 Nov; 43(4):239-45. PubMed ID: 11869061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
    Bartlett JA; Miralles GD; Sevin AD; Silberman M; Pruitt SK; Ottinger J; Gryszowska V; Fiscus SA; Bucy RP;
    AIDS Res Hum Retroviruses; 2002 May; 18(8):535-43. PubMed ID: 12036483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.